Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases
- PMID:2396883
- PMCID: PMC1358164
- DOI: 10.1097/00000658-199009000-00010
Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases
Abstract
Between 1963 and 1968, 57 patients underwent partial ileal bypass (PIB) at the University of Minnesota for primary hypercholesterolemia. Preoperative total plasma cholesterol (TC) was 363.3 +/- 136.8 mg/dL (mean +/- SD) in these patients. Baseline and follow-up TC results demonstrated highly significant (p less than or equal to 0.001) TC reduction, 34% (n = 48), 28% (n = 49), 35% (n = 26), 35% (n = 11), and 30% (n = 25) at 1, 2 to 5, 6 to 10, 11 to 15, and more than 20 years, respectively, after PIB. In 21 patients with baseline, 1-year, and more than 20-year results TC decreased 33% by 1 year and remained 29% less than baseline more than 20 years after surgery (p = NS versus 1 year). Plasma triglyceride results were available in fewer patients, and no statistically significant changes developed after PIB. Two patients (3.5%) underwent PIB reversal, one for intractable diarrhea and one for recurrent nephrolithiasis. In the 25 nonreversed, long-term survivors, no statistically significant weight change was noted. Twenty-four per cent had 0 to 2, 52% had 3 to 5, and 24% had more than 5 bowel movements per day. Subsequent cholecystectomy was required in eight patients, and nephrolithiasis developed in 10 (40%). During 20 to 26 years, most survivors developed clinically apparent atherosclerosis: angina (60%), myocardial infarction (16%), or coronary artery bypass (28%). Coronary heart disease was the predominant cause of death among nonsurvivors (80%). Overall survival rates were 95% 88%, 75%, 59%, 53%, and 41% at 1, 5, 10, 15, 20, and 25 years, respectively, after PIB. Partial ileal bypass leads to highly significant TC reduction, which is sustained, essentially unchanged, more than 20 years after operation. In comparison to available epidemiologic and clinical trial data, these results support the hypothesis that TC reduction has a beneficial effect in patients with hypercholesterolemia.
Similar articles
- Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH).Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al.Buchwald H, et al.N Engl J Med. 1990 Oct 4;323(14):946-55. doi: 10.1056/NEJM199010043231404.N Engl J Med. 1990.PMID:2205799Clinical Trial.
- Partial ileal bypass in type II familial hypercholesterolemia. Eleven-year experience at the Montreal Heart institute.Vaislic CD, Grondin PR, Bourassa MG, Campeau L.Vaislic CD, et al.Am Surg. 1984 Mar;50(3):165-8.Am Surg. 1984.PMID:6367576Clinical Trial.
- Gastric obesity surgery combined with partial ileal bypass for hypercholesterolemia.Buchwald H, Schone JL.Buchwald H, et al.Obes Surg. 1997 Aug;7(4):313-6. doi: 10.1381/096089297765555520.Obes Surg. 1997.PMID:9730516
- Partial ileal bypass in the treatment of hypercholesterolemia.Buchwald H, Fitch LL, Campos CT.Buchwald H, et al.J Fam Pract. 1992 Jul;35(1):69-76.J Fam Pract. 1992.PMID:1301017Review.
- Surgical management of dyslipidemia: clinical and experimental evidence.Moghadasian MH, Frohlich JJ, Saleem M, Hong JM, Qayumi K, Scudamore CH.Moghadasian MH, et al.J Invest Surg. 2001 Mar-Apr;14(2):71-8. doi: 10.1080/08941930152024183.J Invest Surg. 2001.PMID:11396622Review.
Cited by
- Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease. The POSCH Group. Program on the Surgical Control of the Hyperlipidemias.Buchwald H, Campos CT, Matts JP, Fitch LL, Long JM, Varco RL.Buchwald H, et al.Ann Surg. 1992 Oct;216(4):389-98; discussion 398-400. doi: 10.1097/00000658-199210000-00001.Ann Surg. 1992.PMID:1417188Free PMC article.Clinical Trial.
- Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management.Whayne TF Jr.Whayne TF Jr.Int J Angiol. 2017 Jun;26(2):73-77. doi: 10.1055/s-0036-1597129. Epub 2016 Dec 12.Int J Angiol. 2017.PMID:28566931Free PMC article.Review.
- [Sitosterolemia (phytosterolemia)].Lütjohann D.Lütjohann D.Internist (Berl). 2019 Aug;60(8):871-877. doi: 10.1007/s00108-019-0635-2.Internist (Berl). 2019.PMID:31254003Review.German.
- Problems and possible solutions for therapy with statins.Whayne TF Jr.Whayne TF Jr.Int J Angiol. 2013 Jun;22(2):75-82. doi: 10.1055/s-0033-1343358.Int J Angiol. 2013.PMID:24436589Free PMC article.Review.
- Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis.McGlone ER, Siebert M, Dore M, Hope DCD, Davies I, Owen B, Khoo B, Goldin R, Carling D, Bloom S, Le Gall M, Tan TM.McGlone ER, et al.Liver Int. 2023 Sep;43(9):1890-1900. doi: 10.1111/liv.15614. Epub 2023 May 19.Liver Int. 2023.PMID:37208943Free PMC article.
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous